Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 6/20 | 0.41 |
| ▸ | DRD3 | P35462 | 6/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1832369 | 0.88 | PNMT (0.53) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL24663173 | 0.84 | CYP1A2 (0.44) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL9770072 | 0.83 | PNMT (0.55) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL2632968 | 0.82 | NISCH (0.47) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL2632877 | 0.81 | PNMT (0.59) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL16070801 | 0.79 | CYP2D6 (0.52) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL6605633 | 0.79 | PNMT (0.52) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL22933100 | 0.79 | CFD (0.50) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL9618239 | 0.79 | PNMT (0.62) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL2102355 | 0.79 | PNMT (0.52) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787445-B2 | Inhibitors of beta-hydroxylase for treatment of cancer | MIDWESTERN UNIVERSITY (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190300519-A1 | Inhibitors of Beta-Hydroxylase for Treatment of Cancer | MIDWESTERN UNIVERSITY | 2019-10-03 | — | — | US | disclosed |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-7973038-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-20100210638-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787445-B2 | Inhibitors of beta-hydroxylase for treatment of cancer | ASPH, CYP46A1, ALDH7A1 | PNMT 832/4885CYP1A2 82/4885CYP3A4 269/4885 |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, TRPA1 | PNMT 1277/4885CYP1A2 2835/4885CYP3A4 2502/4885 |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | TRPV1, TRPV5, TRPA1 | PNMT 629/4885CYP1A2 2759/4885CYP3A4 3575/4885 |
| US-20100210638-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | PNMT 4080/4885CYP1A2 1815/4885CYP3A4 1164/4885 |
| US-20190300519-A1 | Inhibitors of Beta-Hydroxylase for Treatment of Cancer | ASPH, CYP46A1, ALDH7A1 | PNMT 832/4885CYP1A2 82/4885CYP3A4 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.